Diclofenac Sodium 1% Gel Reduces Size of Seborrheic Keratosis Lesions Better Than Topical Ibuprofen
Topical diclofenac sodium 1% gel was compared with topical ibuprofen gel for the treatment of seborrheic keratosis lesions.
Topical diclofenac sodium 1% gel was compared with topical ibuprofen gel for the treatment of seborrheic keratosis lesions.
New data regarding the prevalence of skin disease in adults aged 70 and older, and the association of cutaneous
diseases and socioeconomic status, sex, and living status is provided.
Investigators aimed to identify the clinical, histologic, and molecular features of atrophic and hypertrophic photoaging.
Seborrheic keratoses (SKs) clearance with a topical solution of 40% hydrogen peroxide was highest among SKs on the face and lowest among SKs on the extremities.
A-101 40 is the first and only FDA-approved topical drug for raised seborrheic keratosis.
The investigators sought to evaluate the efficacy and safety of HP40 vs a vehicle for the treatment of seborrheic keratoses.
Aclaris Therapeutics announced that the Food and Drug Administration has approved Eskata topical solution for the treatment of raised seborrheic keratoses.
3.1% of lesions deemed seborrheic keratoses, were diagnosed as malignancies.